• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上皮性卵巢癌:五年回顾。

Epithelial Ovarian Cancer: A Five Year Review.

机构信息

1st Department of Obstetrics & Gynecology, Papageorgiou Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

3rd Department of Obstetrics & Gynecology, Hippokration Hospital, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

出版信息

Medicina (Kaunas). 2023 Jun 21;59(7):1183. doi: 10.3390/medicina59071183.

DOI:10.3390/medicina59071183
PMID:37511995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10384230/
Abstract

Ovarian cancer is a malignant disease that affects thousands of patients every year. Currently, we use surgical techniques for early-stage cancer and chemotherapy treatment combinations for advanced stage cancer. Several novel therapies are currently being investigated, with gene therapy and stem cell therapy being the corner stone of this investigation. We conducted a thorough search on PubMed and gathered up-to-date information regarding epithelial ovarian cancer therapies. We present, in the current review, all novel treatments that were investigated in this field over the past five years, with a particular focus on local treatment.

摘要

卵巢癌是一种恶性疾病,每年影响数千名患者。目前,我们使用手术技术治疗早期癌症和化疗联合治疗晚期癌症。目前正在研究几种新的疗法,其中基因治疗和干细胞治疗是该研究的基石。我们在 PubMed 上进行了全面搜索,收集了过去五年中关于上皮性卵巢癌治疗的最新信息。在当前的综述中,我们介绍了该领域过去五年中研究的所有新疗法,特别关注局部治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c348/10384230/a0f0868edc41/medicina-59-01183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c348/10384230/a0f0868edc41/medicina-59-01183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c348/10384230/a0f0868edc41/medicina-59-01183-g001.jpg

相似文献

1
Epithelial Ovarian Cancer: A Five Year Review.上皮性卵巢癌:五年回顾。
Medicina (Kaunas). 2023 Jun 21;59(7):1183. doi: 10.3390/medicina59071183.
2
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.高级别上皮性卵巢癌的辅助治疗和术后治疗。
Best Pract Res Clin Obstet Gynaecol. 2022 Jan;78:64-73. doi: 10.1016/j.bpobgyn.2021.09.002. Epub 2021 Sep 16.
3
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
4
Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review.长期多学科综合治疗管理使妊娠合并卵巢癌获得良好结局:病例报告及文献复习。
J Ovarian Res. 2019 Nov 11;12(1):108. doi: 10.1186/s13048-019-0584-3.
5
Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.晚期上皮性卵巢癌女性在确定手术方案前进行新辅助化疗。
Taiwan J Obstet Gynecol. 2018 Oct;57(5):623-624. doi: 10.1016/j.tjog.2018.08.001.
6
New paradigms in the surgical and adjuvant treatment of ovarian cancer.卵巢癌手术及辅助治疗的新范式
Minerva Ginecol. 2014 Apr;66(2):179-92.
7
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.早期上皮性卵巢癌的辅助(术后)化疗。
Cochrane Database Syst Rev. 2015 Dec 17;2015(12):CD004706. doi: 10.1002/14651858.CD004706.pub5.
8
Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.高级卵巢癌:权衡手术的风险和获益。
Clin Obstet Gynecol. 2020 Mar;63(1):74-79. doi: 10.1097/GRF.0000000000000497.
9
Adjuvant Chemotherapy May Not Be Necessary for Women with Stage IC1 Epithelial Ovarian Cancer.对于IC1期上皮性卵巢癌女性患者,辅助化疗可能并非必要。
Curr Med Sci. 2022 Feb;42(1):192-200. doi: 10.1007/s11596-021-2462-7. Epub 2021 Nov 10.
10
Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.治疗前预后营养指数优于血小板计数,可预测上皮性卵巢癌患者的疾病特异性生存。
Int J Gynecol Cancer. 2019 Jul;29(6):1057-1063. doi: 10.1136/ijgc-2019-000492. Epub 2019 Jun 14.

引用本文的文献

1
Interactions between ALKBH5 and reader proteins in tumors: functions and molecular mechanisms.肿瘤中ALKBH5与读取蛋白之间的相互作用:功能与分子机制
Front Oncol. 2025 Sep 1;15:1611007. doi: 10.3389/fonc.2025.1611007. eCollection 2025.
2
Wnt/Ca signaling: Dichotomous roles in regulating tumor progress (Review).Wnt/Ca信号传导:在调节肿瘤进展中的双重作用(综述)
Oncol Lett. 2025 Jun 18;30(2):399. doi: 10.3892/ol.2025.15145. eCollection 2025 Aug.
3
Demographic trends in mortality due to ovarian cancer in the United States, 1999-2020.

本文引用的文献

1
Platin- containing nanoparticles: a recipe for the delivery of curcumin-cisplatin combination chemotherapeutics to mitochondria.含铂纳米颗粒:一种将姜黄素 - 顺铂联合化疗药物递送至线粒体的方法。
Dalton Trans. 2023 Mar 21;52(12):3575-3585. doi: 10.1039/d2dt03149c.
2
Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.拉罗替尼治疗一名晚期子宫多形性脂肪肉瘤患者
J Natl Compr Canc Netw. 2021 Jul 28;19(7):775-779. doi: 10.6004/jnccn.2021.7039.
3
Ultra-small lipid carriers with adjustable release profiles for synergistic treatment of drug-resistant ovarian cancer.
1999 - 2020年美国卵巢癌死亡率的人口统计学趋势
World J Clin Oncol. 2025 Jun 24;16(6):108393. doi: 10.5306/wjco.v16.i6.108393.
4
Polyphyllin I inhibits ovarian cancer growth by inducing G0/G1 phase arrest and inhibiting the c-Myc signaling pathway.重楼皂苷 I 通过诱导 G0/G1 期阻滞和抑制 c-Myc 信号通路来抑制卵巢癌生长。
Med Oncol. 2025 Jun 12;42(7):254. doi: 10.1007/s12032-025-02824-z.
5
5,7,2',6'- Tetrahydroxyflavone affects the progression of ovarian cancer via hsa-miR-495-3p-ACTB/HSP90AA1 pathway.5,7,2',6'-四羟基黄酮通过hsa-miR-495-3p-ACTB/HSP90AA1通路影响卵巢癌进展。
Discov Oncol. 2025 May 19;16(1):817. doi: 10.1007/s12672-025-02570-8.
6
LINC00704 facilitates cell proliferation, migration, and invasion via miR-323a-3p/SLC44A1 axis in epithelial ovarian cancer.LINC00704通过miR-323a-3p/SLC44A1轴促进上皮性卵巢癌的细胞增殖、迁移和侵袭。
Discov Oncol. 2025 Apr 29;16(1):640. doi: 10.1007/s12672-025-01866-z.
7
The Role of GPX1 (rs1050450) Variants in Ovarian Cancer Susceptibility Within a Turkish Population.GPX1(rs1050450)基因变异在土耳其人群卵巢癌易感性中的作用
Cancer Control. 2025 Jan-Dec;32:10732748251332441. doi: 10.1177/10732748251332441. Epub 2025 Apr 14.
8
Fulvic acid exhibits antitumor effects in ovarian cancer cells by upregulating cytochrome P450 family 1 subfamily A member 1 expression.富里酸通过上调细胞色素P450家族1亚家族A成员1的表达,在卵巢癌细胞中发挥抗肿瘤作用。
Discov Oncol. 2025 Apr 12;16(1):523. doi: 10.1007/s12672-025-02236-5.
9
Comprehensive bioinformatics analysis of co-mutation of and reveals prognostic effect and influences on the immune infiltration in ovarian serous cystadenocarcinoma.对[具体基因1]和[具体基因2]共突变的综合生物信息学分析揭示了其在卵巢浆液性囊腺癌中的预后作用及对免疫浸润的影响。
Transl Cancer Res. 2025 Feb 28;14(2):1282-1296. doi: 10.21037/tcr-24-1596. Epub 2025 Feb 17.
10
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.上皮性卵巢癌中药物治疗敏感性预测性蛋白质基因组生物标志物的机遇。
Front Oncol. 2025 Jan 7;14:1503107. doi: 10.3389/fonc.2024.1503107. eCollection 2024.
具有可调节释放曲线的超小型脂质载体用于协同治疗耐药性卵巢癌。
Nanotechnology. 2022 Jun 9;33(35). doi: 10.1088/1361-6528/ac18d6.
4
Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.大阴离子脂质体使 TLR7/8 激动剂靶向腹腔内递送至重极化卵巢肿瘤的微环境。
Bioconjug Chem. 2021 Aug 18;32(8):1581-1592. doi: 10.1021/acs.bioconjchem.1c00139. Epub 2021 Jul 21.
5
Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.共价微管稳定剂在紫杉烷耐药卵巢癌模型中的疗效。
Molecules. 2021 Jul 3;26(13):4077. doi: 10.3390/molecules26134077.
6
Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness.细胞外基质蛋白-1 分泌型异构体通过增加选择性 mRNA 剪接和干性促进卵巢癌。
Nat Commun. 2021 Jul 9;12(1):4230. doi: 10.1038/s41467-021-24315-1.
7
SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors.SENTI-101,一种经过基因工程改造表达 IL12 和 IL21 的间充质基质细胞制剂,在腹膜实体瘤的临床前模型中诱导局部和持久的抗肿瘤免疫。
Mol Cancer Ther. 2021 Sep;20(9):1508-1520. doi: 10.1158/1535-7163.MCT-21-0030. Epub 2021 Jul 1.
8
Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging.利用质谱成像技术研究奥沙利铂在接受热腹腔内化疗(HIPEC)治疗的结直肠和阑尾来源腹膜转移患者卵巢中的渗透情况。
Pleura Peritoneum. 2021 Mar 24;6(2):67-74. doi: 10.1515/pp-2020-0149. eCollection 2021 Jun.
9
Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer.复发性卵巢癌阴道和直肠周围病变的放射治疗
Gynecol Oncol Rep. 2021 Jun 9;37:100808. doi: 10.1016/j.gore.2021.100808. eCollection 2021 Aug.
10
A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation.一种递送新抗原集合的合成DNA疫苗通过强大的T细胞生成来控制异质性、多灶性小鼠肺癌和卵巢癌。
Mol Ther Oncolytics. 2021 Apr 16;21:278-287. doi: 10.1016/j.omto.2021.04.005. eCollection 2021 Jun 25.